Aion Therapeutic Inc.

Vancouver, A1 · Founded 2011 · CIK 0001521250 · Biotech · Public

Monoclonal antibody therapeutics for autoimmune and inflammatory diseases

red.co →
Grants
—
No SBIR or STTR on record
Sector median: 1
Raised
$5.9M
5 Form D · Feb 2024
32 months since last filing
Contracts
—
No federal contracts on record
Patents
—
No published records under this name
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Private capital raisedForm D · SEC$25,000
Private capital raisedForm D · SEC$9,168
Private capital raisedForm D · SEC$10,082
Private capital raisedForm D · SEC$34,216
Private capital raisedForm D · SEC$5,793,125
Form D · SEC

Peer position

Biotech · 4373 companies · ranked on federal contract value
Biotech companies ranked by federal contract value
#CompanyContractsDisclosed equity
1451COMETA THERAPEUTICS INC——
1452ProPhase Labs, Inc.—$8.4M
1453Surf Lakes Global, Inc.—$720K
1454Aion Therapeutic Inc.—$5.9M
1455Nistron, L.L.C.——
1456VIAMUNE, INC.——
1457Neuralexo, LLC——

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Founders & Team

From Form D filings · 14 related persons
  • Paul CrathDirector
  • Sabino Di PaolaExecutive Officer
  • Robin DowDirector · Executive Officer
  • Anthony, Dr. HallDirector
  • Larry HooverDirector
  • Larry HorwitzDirector
  • Sara Lee IrwinDirector
  • Rakesh MalhotraExecutive Officer
  • Zamora MichaelExecutive Officer
  • George NewmanDirector
  • Paul PitmanExecutive Officer
  • Robert SchellenbergDirector
  • Graham SimmondsExecutive Officer
  • Gary SmithExecutive Officer

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.